Janus Henderson Group PLC Avrobio, Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $945,353 - $2.96 Million	-732,832 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $2.53 Million - $4.43 Million	732,832 New	732,832 $2.83 Million
Q3 2021 Nov 16, 2021	SELL	$5.53 - $9.28 $121,825 - $204,438	-22,030 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.84 - $12.6 $2.34 Million - $3.77 Million	-298,963 Reduced 93.14%	22,030 $196,000
Q1 2021 May 17, 2021	BUY	$10.54 - $19.3 $2.2 Million - $4.03 Million	208,611 Added 185.63%	320,993 $4.07 Million
Q4 2020 Feb 16, 2021	BUY	$12.79 - $17.1 $619,611 - $828,409	48,445 Added 75.77%	112,382 $1.57 Million
Q3 2020 Nov 16, 2020	BUY	$12.99 - $19.41 $830,541 - $1.24 Million	63,937 New	63,937 $834,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.